Stool transplant plus antibody drug shows promise against recurrent c. diff in IBD patients

NCT ID NCT03829475

Completed Prevention Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining a fecal microbiota transplant (FMT) with the drug bezlotoxumab could prevent repeat Clostridium difficile infections in people with inflammatory bowel disease (IBD). Sixty-one adults with at least two prior C. diff infections were randomly assigned to receive FMT plus bezlotoxumab or FMT plus a placebo. Participants were followed for three months to see if the infection came back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fecal microbiota transplantation (FMT) plus bezlotoxumab (Zinplava)
What this could lead to: If it works, this combination could offer a more effective way to prevent repeat C. diff infections in people with inflammatory bowel disease.
What could go wrong: This is a small, early-phase study (61 participants) and results may not apply to everyone. The treatment involves infusing donor stool, which carries unknown infection risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLOSTRIDIUM DIFFICILE INFECTION INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.